SEC Form 4 · accession 0001209191-17-008399
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Parini
Officer — EVP, CL&AO
Period of report
Feb 3, 2017
Accepted (ET)
Feb 7, 2017 · 4:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 3, 2017 | A | 18,204 | $0.00 | A | 28,554 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $86.52 | Feb 3, 2017 | A | 37,278 | A | — | Feb 2, 2027 | Common Stock | 37,278 | 37,278 | D |
Explanation of responses
- F1Restricted stock unit award that vests in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020.
- F2The option vests in 16 quarterly installments from 02/03/2017.